Kiniksa Pharmaceuticals International, plc
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Kiniksa Pharmaceuticals International is a biopharmaceutical company focused on developing and commercializing medicines for diseases with significant unmet need, including recurrent pericarditis and other inflammatory conditions. Its lead product, ARCALYST (rilonacept), is approved for recurrent pericarditis, and the company also advances a pipeline of additional immune and inflammatory disease candidates.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Ragosa MarkCHIEF FINANCIAL OFFICER | Sell | $966K | 10,502at $92.03 | Nov 2, 2026 |
| Ragosa MarkCHIEF FINANCIAL OFFICER | Sell | $1.28M | 14,027at $91.40 | Nov 2, 2026 |
| Ragosa MarkCHIEF FINANCIAL OFFICER | Sell | $21K | 220at $94.01 | Nov 2, 2026 |
| Ragosa MarkCHIEF FINANCIAL OFFICER | Sell | $1.12M | 12,034at $93.13 | Nov 2, 2026 |
| Patel Sanj KCHAIRMAN & CEO | Sell | $3.49M | 38,364at $91.03 | Nov 2, 2026 |
| Patel Sanj KCHAIRMAN & CEO | Sell | $2.49M | 26,781at $93.06 | Nov 2, 2026 |
| Patel Sanj KCHAIRMAN & CEO | Sell | $2.22M | 24,188at $91.83 | Nov 2, 2026 |
| Patel Sanj KCHAIRMAN & CEO | Sell | $1.73M | 18,685at $92.77 | Oct 30, 2026 |
| Paolini John F.CHIEF MEDICAL OFFICER | Sell | $1.57M | 16,810at $93.42 | Nov 2, 2026 |
| Paolini John F.CHIEF MEDICAL OFFICER | Sell | $1.49M | 16,056at $92.85 | Oct 30, 2026 |
| Patel Sanj KCHAIRMAN & CEO | Sell | $1.49M | 15,903at $93.62 | Oct 30, 2026 |
| Patel Sanj KCHAIRMAN & CEO | Sell | $842K | 8,888at $94.72 | Oct 30, 2026 |
| Paolini John F.CHIEF MEDICAL OFFICER | Sell | $642K | 6,841at $93.91 | Oct 30, 2026 |
| Paolini John F.CHIEF MEDICAL OFFICER | Sell | $457K | 4,821at $94.86 | Oct 30, 2026 |
| Patel Sanj KCHAIRMAN & CEO | Sell | $432K | 4,584at $94.25 | Nov 3, 2026 |
| Patel Sanj KCHAIRMAN & CEO | Sell | $431K | 4,490at $95.97 | Oct 30, 2026 |
| Paolini John F.CHIEF MEDICAL OFFICER | Sell | $384K | 4,000at $95.97 | Oct 30, 2026 |
| Patel Sanj KCHAIRMAN & CEO | Sell | $225K | 2,316at $97.34 | Oct 30, 2026 |
| Paolini John F.CHIEF MEDICAL OFFICER | Sell | $211K | 2,155at $97.77 | Oct 30, 2026 |
| Paolini John F.CHIEF MEDICAL OFFICER | Sell | $187K | 1,925at $97.06 | Oct 30, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable KNSA activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.